Sipuleucel-T

Adenocarcinoma of the Prostate

DendreonCell therapyPhase 3Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 81/ 100

Competitive context

97 Active assets in the Adenocarcinoma of the Prostate cohort.

Asset / Sponsor	Phase	Rating
Docetaxel Instituto do Cancer do Estado de São Paulo	Phase 3	BBB
Degarelix Canadian Cancer Trials Group	Phase 3	BB
PREDNISONE TABLETS Mayo Clinic	Phase 3	BB
NILUTAMIDE SWOG Cancer Research Network	Phase 3	BB
Cyclophosphamide Beijing Biotech	Phase 2	BB

View all 50 →

Same molecule, other indications

Sipuleucel-T is also rated in:

metastatic prostate carcinomaDormant

BB

Indicative ·

68 / 100

prostate cancerDormant

BB

Indicative ·

66 / 100

castration-resistant prostate carcinomaDormant

BB

Indicative ·

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.